Pharmaceuticals Middle East

Middle East Geographic Atrophy Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Middle East Geographic Atrophy Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Middle East · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $37.1 Mn Placeholder estimate
Estimate 2025 $46.6 Mn 3.7% of the global market
Projected 2034 $365.2 Mn 683.5% Adds $318.6 Mn over 9 forecast years
CAGR 2025–2034 25.7% Faster than 92% of 180 Pharmaceuticals markets here
Key players 5
  • Middle East is 3.73% of the global market.
  • Among regions, the largest is North America at $537.5 Mn.
  • Fastest growing: APAC at 26.5% a year.
  • Middle East ranks 5th of 6 by size among regions.

Market size projection

Middle East

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$318.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Geographic Atrophy Treatment Market market size by year, Middle East
YearMarket sizeChange that yearSince 2025
2024 (estimate) $37.1 Mn — —
2025 (base) $46.6 Mn +$9.5 Mn —
2026 (forecast) $58.6 Mn +$12.0 Mn +25.7%
2027 (forecast) $73.6 Mn +$15.1 Mn +58%
2028 (forecast) $92.6 Mn +$18.9 Mn +98.6%
2029 (forecast) $116.4 Mn +$23.8 Mn +149.7%
2030 (forecast) $146.3 Mn +$29.9 Mn +213.8%
2031 (forecast) $183.9 Mn +$37.6 Mn +294.5%
2032 (forecast) $231.1 Mn +$47.3 Mn +395.8%
2033 (forecast) $290.5 Mn +$59.4 Mn +523.3%
2034 (forecast) $365.2 Mn +$74.7 Mn +683.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Middle East Geographic Atrophy Treatment Market Analysis at a glance
Market size, 2025$46.6 Mn placeholder estimate
Forecast, 2034$365.2 Mn placeholder estimate
Growth (CAGR), 2025–203425.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, route and end user (see all)
Key playersApellis Pharmaceuticals, Astellas Pharma Inc., Roche, Novartis AG, Annexon Biosciences (see all)
Active clinical trials1 in Middle EastSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Middle East Geographic Atrophy Treatment Market Analysis Executive Summary

Geographic atrophy treatments slow the advanced form of dry age-related macular degeneration that causes vision loss.

Key segments of the geographic Atrophy Treatment market include drug (Complement C3 Inhibitors, Complement C5 Inhibitors and Pipeline Therapies) and route (Intravitreal Injection).

Bar chart: Middle East Geographic Atrophy Treatment market size, 2024–2034, placeholder estimates. $37.1 Mn in 2024, $46.6 Mn in 2025 and $365.2 Mn in 2034, 25.7% CAGR.
Middle East Geographic Atrophy Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Middle East Geographic Atrophy Treatment Market Dynamics

Market Growth Drivers

An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the geographic Atrophy Treatment market.

Opportunity

Longer-acting treatments, home-based care and screening in emerging markets give the geographic Atrophy Treatment market room to grow.

Market Restraints

High costs of new treatments, specialist shortages, low awareness and limited reimbursement in some countries hold back the geographic Atrophy Treatment market.

Competitive Landscape for Geographic Atrophy Treatment Market in Middle East

The geographic Atrophy Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Geographic Atrophy Treatment Market in Middle East

Geographic Atrophy Treatment in Middle East: rules, payment and research

In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)⁠[1], EDE (UAE)⁠[2], Ministry of Public Health (Qatar)⁠[3] and Ministry of Health (Israel)⁠[4]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)⁠[5], mandatory health insurance (UAE)⁠[6], public care and compulsory insurance (Qatar)⁠[3] and four health funds (Israel)⁠[4]. ClinicalTrials.gov lists 1 study on Geographic Atrophy Treatment that is recruiting, active or about to start in Middle East.⁠[7]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Emirates Drug Establishment. Checked 14 Nov 2026.

[3] Ministry of Public Health, Qatar. Checked 19 Nov 2026.

[4] Israel Ministry of Health. Checked 19 Nov 2026.

[5] Council of Health Insurance. Checked 14 Nov 2026.

[6] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.

[7] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for geographic Atrophy Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Geographic Atrophy Treatment right now, from free public sources.

Clinical trials

1 active trial in UAE, Saudi Arabia, Israel, Yemen, Jordan, Lebanon, Qatar, Syria, Palestine and Iraq

Recruiting, about to start, or running now. Counted across the 10 countries we report on in Middle East.

Top trial sponsors (worldwide)

  1. Ocugen 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Complement Therapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Roche 2 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Annexon Biosciences 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Regeneron Pharmaceuticals 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Geographic Atrophy Treatment in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Geographic Atrophy Treatment market in Middle East?
Placeholder estimate: about $46.6 Mn in 2025, rising to about $365.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Geographic Atrophy Treatment market in Middle East growing?
Placeholder estimate: about 25.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Geographic Atrophy Treatment market report cover?
The report splits the market by drug (Complement C3 Inhibitors, Complement C5 Inhibitors, Pipeline Therapies), route (Intravitreal Injection) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Geographic Atrophy Treatment market?
Key players include Apellis Pharmaceuticals, Astellas Pharma Inc., Roche, Novartis AG and Annexon Biosciences.
What is driving the Geographic Atrophy Treatment market?
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the geographic Atrophy Treatment market.
How many clinical trials on Geographic Atrophy Treatment are running in Middle East?
1 study is recruiting, active or about to start in Middle East, counted across the 10 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.
How much research is published on Geographic Atrophy Treatment?
PubMed lists 632 papers on Geographic Atrophy Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Middle East

See all

Related on eye health and geriatric

See the topic